Gonapeptyl Daily (Triptorelin Acetate)

Gonapeptyl Daily is indicated for several hormone‑dependent conditions where suppression of sex hormone production is desired. It is commonly prescribed as part of endocrine therapy for malignancies and benign disorders that respond to reduced testosterone or estrogen levels.

• Treatment of advanced or metastatic prostate cancer in men.
• Management of endometriosis‑associated pain and lesion progression.
• Reduction of uterine fibroid size and related bleeding.
• Control of central precocious puberty in children.
• Adjunct therapy before radiotherapy or surgery for hormone‑sensitive tumors.

The pharmacologic action of triptorelin acetate can produce a range of adverse reactions, most of which are related to the abrupt decline in sex hormones.

Common

• Hot flashes or night sweats.
• Decreased libido or erectile dysfunction.
• Headache or mild dizziness.
• Injection site pain, redness, or swelling.

Serious

• Severe allergic reaction with rash, itching, or swelling of the face.
• Cardiovascular events such as hypertension or arrhythmia.
• Bone density loss leading to increased fracture risk.

Because Gonapeptyl Daily alters hormone levels, careful assessment is required before initiation and during treatment to minimize potential complications. Patients should be evaluated for underlying conditions that could be worsened by gonadotropin suppression.

• Avoid use in patients with known hypersensitivity to triptorelin or any excipients.
• Monitor cardiovascular status, especially in individuals with hypertension or heart disease.
• Assess bone health periodically, as long‑term therapy may reduce bone mineral density.
• Use caution in patients with liver or renal impairment; dose adjustments may be needed.
• Discontinue or adjust therapy in cases of severe allergic reaction or anaphylaxis.
• Counsel women of childbearing potential about unknown pregnancy safety and advise effective contraception.

Triptorelin acetate can interact with other medicines that influence hormone pathways, cardiovascular function, or hepatic metabolism, potentially altering its effectiveness or safety profile. Clinicians should review a patient’s full medication list before prescribing.

Avoid

• Concomitant use with other GnRH agonists or antagonists, which may cause excessive hormone suppression.
• Strong CYP3A4 inducers that could reduce triptorelin exposure (e.g., rifampin, carbamazepine).

Use with caution

• Anticoagulants, as hormonal changes may affect coagulation parameters.
• Hormone replacement therapy, which can counteract the intended suppression.
• Medications affecting bone metabolism (e.g., bisphosphonates, glucocorticoids).